PhotoPharmics is a privately held, clinical-stage medical device company based in Utah, specializing in non-invasive light therapy treatments for neurodegenerative diseases. With over 30 years of research experience, the company's founders previously developed light-based solutions for conditions like seasonal affective disorder and sleep disorders, which were acquired by Philips-Respironics in 2007 .

Currently, PhotoPharmics is advancing its Celeste® device, designed to deliver specialized phototherapy to the eyes, aiming to improve both motor and non-motor symptoms of Parkinson’s disease. The device is under evaluation in the "Light for PD" trial, the largest phototherapy study for Parkinson’s to date, involving 300 participants using the device daily at home during routine evening activities . This passive, non-invasive therapy complements existing treatments without requiring changes to medication regimens.